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Background
The K65R substitution can cause extensive cross-resistance
among currently used NRTIs, yet this mutation has rarely
been observed among subtype B infected individuals who
receive antiretroviral (ARV) drugs.
Methods
We evaluated the incidence of K65R in subtype C patients
in Botswana, who received ARV therapy in the context of
first and second line regimens by studying the reverse
transcriptase (RT) genotypes of 23 individuals who failed
therapy, while on combination regimens that included
ddI and d4T.
Results
Ten of these individuals had initiated treatment with ddI/
d4T-based regimens while 13 had started therapy with
ZDV/3TC/NVP or ZDV/3TC/EFV prior to switching to
ddI-and/or d4T-containing combinations. Of the 23
patients, 7 possessed K65R and no-one possessed L74V
after a median exposure to combination ddI/d4T of only
eight months (range 4–18 months). In contrast, none of
13 patients who received 3TC/ZDV as initial therapy prior
to d4T/ddI developed K65R, although most of them
developed thymidine-associated mutations (TAMs); this
is potentially due to antagonism between TAMs and
K65R. In tissue culture studies, K65R was detected after
only 12 weeks in 4/4 and 3/4 selections with Tenofovir
and ddI, respectively, but far longer periods were required
for relatively infrequent selection of K65R by Tenofovir
with subtype B viruses (>40 weeks; 2/7 selections).
Conclusion
K65R may emerge at higher frequency in individuals
infected with subtype C viruses who experience treatment
with certain NRTIs, establishing the need to monitor for
the presence of this mutation and its possible transmis-
sion.
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